Dr. Thomas Hanke

Dr. Thomas Hanke


Thomas builds on 30 years of hands-on experience in research and drug discovery in academia, biotech and pharma. Fostering innovation and improvement, he develops and deploys novel business models to accelerate the translation of academic concepts to investable therapeutic product candidates across modalities.

At Evotec, Thomas is responsible for a global portfolio of strategic academic partnerships, pre-seed incubators and early-stage investments with 20 different industry partners and over 50 top-tier academic institutions. He holds Non-Executive Director positions at Tubulis (Munich), Dark Blue Therapeutics (Oxford), Autobahn Labs (Palo Alto) and Argobio (Paris, observer).

Since 2022, Thomas co-leads the working group ’Technologie Transfer’ at Bio-Deutschland.

From 2013 to 2016, Thomas oversaw Evotec’s proprietary drug discovery and development portfolio in inflammation and immuno-oncology.

From 2007 to 2013, Thomas was Sourcing Director at Novo Nordisk where he identified, evaluated and initiated pipeline-building partnerships within autoimmune / inflammatory diseases, haemophilia, growth disorders and protein technologies.

From 2000 to 2007, Thomas was co-founder and Chief Scientific Officer of TeGenero, developing first-in-class immunomodulatory monoclonal antibodies.

Until 2000, Thomas was Assistant Professor for Immunobiology at the University of Würzburg, following a PostDoc at the University of California, Berkeley, where he studied the activation and differentiation of lymphocytes. Thomas received his PhD in Biology from the University of Würzburg in 1995.